Clinical trials: Hematologic and Lymphocytic Disorder
Hemophilia
Blood Flow Restriction in Improving Muscle Strength of Patients With Hemophilic Ankle Arthropathy
Background. The main physical sequela of patients with hemophilia is the development of a progressive, degenerative intra-articular lesion, known as hemophilic arthropathy).
- Trial name
- NCT06261593
- Testing
- Blood flow restriction
- Where
- Spain
- Volunteers
- 31 people
- Sponsor
- Investigación en Hemofilia y Fisioterapia
Vitamin c, Thalassemia Major
Role of Vitamin C to Augment Iron Chelation With DFP or DFX
role of Vit C to Augment iron chelation with DFP or DFX in thalassemic patients.
- Conditions
- Vitamin c, Thalassemia Major, Iron Chelation
- Trial name
- NCT02083575
- Testing
- Vitamin C, Defriprone, deferisarox, deferiprone , deferesarox
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Ain Shams University
Sickle Cell Anemia
Gum Arabic as Fetal Hemoglobin Agent in Sickle Cell Anemia
The purpose of this study is to determine whether Gum Arabic is effective as fetal hemoglobin inducing agent for sickle cell anemia patients.
- Trial name
- NCT02467257
- Testing
- Gum Arabic
- Where
- Sudan
- Volunteers
- 47 people
- Sponsor
- Al-Neelain University
Neural Tube Defects, Folic Acid Deficiency
Using Iodized Salt to Improve Serum Folate, B12 and Iron Levels
Question: How effective is fortified iodized salt in increasing serum concentrations of folate, B12 and iron among non-pregnant and non-lactating women of reproductive age? Hypothesis: Micronutrient fortified iodized salt can…
- Conditions
- Neural Tube Defects, Folic Acid Deficiency, Spina Bifida, Anencephaly-Spina Bifida
- Trial name
- NCT06904612
- Testing
- Micronutrient fortified iodized salt
- Where
- 2 sites in United States, India
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Hydrocephalus and Neuroscience Institute
Multiple Myeloma
IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma
This is an open-label, multi-centre, randomised Phase III study, looking at a series of 480 patients up to the age of 65 with newly diagnosed multiple myeloma (MM) not previously treated.
- Trial name
- NCT00200681
- Testing
- Velcade
- Where
- France
- Volunteers
- 493 people
- Sponsor
- Nantes University Hospital
Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia
Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)
This exploratory study is to investigate the efficacy, safety and tolerability of Lusutrombopag in the treatment of primary immune thrombocytopenia in Chinese patients who have failed first-line therapy
- Trial name
- NCT06287567
- Testing
- Lusutrombopag Oral Tablet
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Background The development of new technologies now allow scientists to investigate the molecular basis and clinical manifestations of monoclonal B cell lymphocytosis (MBL), chronic lymphocytic leukemia(CLL)/small lymphocytic…
- Conditions
- Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma, Monoclonal B-Cell Lymphocytosis, Small Lymphocytic Lymphoma
- Trial name
- NCT00923507
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma
This is a Phase I dose-escalation study to evaluate the safety, tolerability and preliminary efficacy of an autologous BCMA-targeting RNA-engineered CAR T-cell therapy in patients with Relapsed/Refractory Multiple Myeloma.
- Trial name
- DC15-MM-01 (NCT06304636)
- Testing
- Descartes-15
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Cartesian Therapeutics
Meningococcal Vaccine
Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age
The aim of this study is to evaluate the safety, tolerability, and immunogenicity of 2 doses of Trumenba® (on a 0- and 6-month schedule) in immunocompromised participants by functionally assessing antibody production in asplenic…
- Trial name
- NCT04893811
- Testing
- Trumenba
- Where
- 14 sites in Czechia, Poland and 1 more
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Pfizer
Sickle Cell Disease
Assessing Physical Function in Sickle Cell Patients Taking Voxelotor
Voxelotor is a novel hemoglobin polymerization inhibitor which has been demonstrated to reduce hemolysis and improve hemoglobin levels.
- Trial name
- NCT06023199
- Testing
- Voxelotor
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Inova Health Care Services
Immune Thrombocytopenia
A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013
This is a retrospective analysis of children (≤21years old) who received clinical treatment with either Romiplostim or Eltrombopag at 2 medical centers from 2009-2013.
- Trial name
- NCT01974232
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Weill Medical College of Cornell University
Chronic Myeloid Leukemia
TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study
Advances in Chronic Myeloid Leukemia (CML) therapy led to an expected survival prolongation of > 20 years after diagnosis. So far, discontinuation of tyrosine kinase inhibitors led to recurrence of disease in the majority of…
- Trial name
- TIGER (NCT01657604)
- Testing
- Peginterferon α2b, Nilotinib
- Where
- 112 sites in Czechia, Germany and 1 more
- Volunteers
- 717 people
- Sponsor
- University of Jena
Iron Deficiency Anemia, Constipation
Investigating the Effects of Iron on the Gastrointestinal Tract
Many patients that are prescribed iron report gastrointestinal side effects. This research project aims to investigate if the gastrointestinal symptoms of taking iron supplementation are related to changes in gases produced by…
- Trial name
- GI-iron (NCT04253652)
- Testing
- Fasted breath samples, IBS-SSS, Daily diary
- Where
- United Kingdom
- Volunteers
- 155 people
- Sponsor
- The Functional Gut Clinic
Leukemia
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid…
- Trial name
- QuANTUM-WILD (NCT06578247)
- Testing
- Quizartinib, Chemotherapy
- Where
- 284 sites in United States, Australia and 26 more
- Volunteers
- 700 people
- Sponsor
- Daiichi Sankyo
Lymphoma, Small Intestine Cancer
ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00016172
- Testing
- pegylated liposomal doxorubicin hydrochloride, picoplatin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Fanconi Anemia
Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion of RP-L102
Long-Term Follow-up: Phase I/II clinical study to evaluate the safety and efficacy of the infusion of RP-L102
- Trial name
- NCT07527975
- Testing
- RP-L102
- Where
- 3 sites in United States, Spain and 1 more
- Volunteers
- 14 people
- Sponsor
- Rocket Pharmaceuticals Inc.
Nephropathy, Sickle Cell Anemia
Losartan to Reverse Sickle Nephropathy
Sickle cell disease causes kidney damage with increasing age, leading to chronic kidney disease and renal failure in nearly one third of patients with sickle cell disease.
- Trial name
- NCT01479439
- Testing
- Losartan
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Myelofibrosis
Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)
This is a Phase IB, open-label, dose-finding study of the JAK 1 and 2 inhibitor ruxolitinib in patients with myelofibrosis (MF).
- Trial name
- NCT01317875
- Testing
- Ruxolitinib
- Where
- 18 sites in United States, Austria and 6 more
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation
Chronic Myelomonocytic Leukemia
Lenalidomide in Patients With Chronic Myelomonocytic Leukemia
In a phase I study the investigators plan to investigate safety and toxicity of lenalidomide in patients with Chronic Myelomonocytic Leukemia (CMML). A phase II study will be started once an optimal dose has been found.
- Trial name
- NCT01368757
- Testing
- Revlimid
- Where
- 10 sites in Austria
- Volunteers
- 30 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Relapsed/Refractory Multiple Myeloma (MM)
Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma
A Phase 1a/1b Open-Label Study with Dose Escalation and Expansion Phases to Evaluate Safety and Preliminary Efficacy of Naïve HBI0101 CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma.
- Trial name
- NCT07333430
- Testing
- Naive HBI0101 CAR-T
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Hadassah Medical Organization
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.